Long-term Extension Study of Ligelizumab in Food Allergy

Phase 3 Terminated 163 enrolled Novartis Pharmaceuticals

Non-randomizedParallel-groupQuadruple-blindTreatment

Summary

This was an extension study to evaluate the long-term safety and efficacy of ligelizumab in participants who completed a ligelizumab Phase III study in food allergy.

Timeline

Start: 2023-04-27
Primary completion: 2025-03-06
Completion: 2025-03-06

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Publications

Ghelli C, Costanzo G, Canonica GW, Heffler E, Paoletti G. New evidence in food allergies treatment. Curr Opin Allergy Clin Immunol. 2024 Aug 1;24(4):251-256. doi: 10.1097/ACI.0000000000000999. Epub 2024 May 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ligelizumab	Monoclonal antibody	120 mg	—
Subject	Ligelizumab	Monoclonal antibody	240 mg	—